To celebrate the release of GATK 4.0, we are giving away free credits for running the GATK4 Best Practices pipelines in FireCloud, our secure online analysis portal. It’s first come first serve, so sign up now to claim your free credits worth $250. Sponsored by Google Cloud. Learn more at

Cancer variant calling workflow with mutect and changes/additions to the GATK best practices

alons123alons123 HerzliyaMember

Hi all,

I'm working on a cancer variant calling workflow (DNAseq) with MuTect as the variant caller, rather than HaplotypeCaller (due to it's low AF intolerance).
I've gone through the forum and couldn't find a full answer to my inquiry. My question has 2 parts actually:

  1. what changes/additions should I implement in my pipeline/workflow to the GATK Best practices workflow for variant analysis to make it more suitable for cancer variant calling with MuTect, taking into account that I don't have a normal tissue sample, just tumor and an hg19 reference from the bundle:

  2. Is there a difference between the recommended "--known" variants/sites of the GATK's best practices workflow for general variant calling and the one for cancer variant calling with MuTect as the variant caller? Specifically to this article:

Thank you very much in advance,


Sign In or Register to comment.